Breakwater Capital Group Decreases Stake in Pfizer Inc. (NYSE:PFE)

Breakwater Capital Group lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 9.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 73,181 shares of the biopharmaceutical company’s stock after selling 7,358 shares during the quarter. Breakwater Capital Group’s holdings in Pfizer were worth $1,941,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Thoroughbred Financial Services LLC lifted its holdings in shares of Pfizer by 102.9% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 32,173 shares of the biopharmaceutical company’s stock valued at $900,000 after acquiring an additional 16,313 shares during the last quarter. Redwood Wealth Management Group LLC raised its position in Pfizer by 6.0% during the second quarter. Redwood Wealth Management Group LLC now owns 24,865 shares of the biopharmaceutical company’s stock valued at $696,000 after purchasing an additional 1,405 shares during the period. Valley Forge Investment Consultants Inc. ADV purchased a new stake in Pfizer during the second quarter valued at approximately $169,000. Bcwm LLC bought a new stake in shares of Pfizer in the 2nd quarter valued at approximately $4,781,000. Finally, Bruce & Co. Inc. increased its position in shares of Pfizer by 2.9% during the 2nd quarter. Bruce & Co. Inc. now owns 276,400 shares of the biopharmaceutical company’s stock valued at $7,734,000 after purchasing an additional 7,900 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.3 %

NYSE:PFE opened at $26.79 on Tuesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a 50-day simple moving average of $26.16 and a 200-day simple moving average of $28.04. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The firm has a market cap of $151.82 billion, a P/E ratio of 36.20, a P/E/G ratio of 0.63 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the prior year, the business earned ($0.17) earnings per share. Pfizer’s revenue was up 31.2% on a year-over-year basis. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.42%. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is 232.43%.

Insiders Place Their Bets

In other news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

PFE has been the subject of a number of analyst reports. Sanford C. Bernstein started coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. Citigroup initiated coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. Wolfe Research started coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock. Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Finally, Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.